Double-blind Randomized Parallel Arm Study of 3 Anti CD20 Monoclonal Antibodies in Patients with Moderate to Severe, Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate Based Therapy. Efficacy Safety & Immunogenicity Results

被引：0

作者：

Haridas, Vikram ^{[1
]}

Katta, Rahul ^{[2
,3
]}

Nalawade, Ajit ^{[4
]}

Kharkar, Sandeep ^{[5
]}

Zhdan, Vyacheslav ^{[6
]}

Garmish, Olena ^{[7
]}

Lopez-Lazaro, Luis ^{[8
]}

Batra, Sonica ^{[9
]}

Kankanwadi, Suresh ^{[10
]}

机构：

[1] Sushruta Multispecial Hosp, Hubballi, Karnataka, India

[2] Katta Hosp, Jaipur, Rajasthan, India

[3] SR Kalla Mem Gen Hosp, Jaipur, Rajasthan, India

[4] Inamdar Multispecialty Hosp, Pune, Maharashtra, India

[5] CARE Hosp, Nagpur, Maharashtra, India

[6] MV Sklifosovskyi Poltava Reg Clin Hosp, Ukrainian Med Stomatol Acad, Higher State Educ Inst Ukraine, Dept Rheumatol, Poltava, Ukraine

[7] NAMSU, SI NS MD Strazhesko Inst Cardiol, Kiev, Ukraine

[8] Dr Reddys Labs SA, Basel, Switzerland

[9] Dr Reddys Labs Ltd, Bachupally, Telangana, India

[10] Dr Reddys Labs EU Ltd, Cambridge, England

来源：

JOURNAL OF RHEUMATOLOGY | 2018年 / 45卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

224

引用

页码：1052 / 1052

页数：1

共 50 条

[41] Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Weinblatt, Michael
Bingham, Clifton
Burmester, Gerd
Bykerk, V. P.
Furst, Daniel E.
Mariette, Xavier
van der Heijde, Desiree
Tatla, Daljit
Arendt, Catherine
Mountian, Irina
VanLunen, Brenda
Emery, Paul
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[42] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
Cai, L.
Gu, J.
Zheng, J.
Zheng, M.
Wang, G.
Xi, L. -Y.
Hao, F.
Liu, X. -M.
Sun, Q. -N.
Wang, Y.
Lai, W.
Fang, H.
Tu, Y. -T.
Sun, Q.
Chen, J.
Gao, X. -H.
Gu, Y.
Teixeira, H. D.
Zhang, J. -Z.
Okun, M. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
[43] Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Papp, K.
Reich, K.
Blauvelt, A.
Baran, W.
Bolduc, C.
Toth, D.
Gottlieb, A. B.
Thaci, D.
Li, J.
Nirula, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
[44] Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-Blind, placebo-controlled study
Papp, Kim
Reich, Kristian
Leonardi, Craig
Paul, Carle
Blauvelt, Andrew
Baran, Wojciech
Bolduc, Chantal
Toth, Darryl
Langley, Richard G.
Cather, Jennifer
Gottlieb, Alice
Thaci, Diamant
Milmont, Cassandra E.
Lim, Joanne
Klekotka, Paul
Kricorian, Greg
Nirula, Ajay
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
[45] Efficacy and Safety of Monotherapy with Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Taylor, Peter C.
Schiff, Michael
Wang, Qingmin
Jiang, Yusang
Kurrasch, Regina
Daga, Shruti
Rao, Ravi
Hsu, Benjamin
Tak, Paul-Peter
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[46] Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Cestari, Tania F.
Souza, Cacilda da Silva
Azulay-Abulafia, Luna
Romiti, Ricardo
Carvalho, Andre V. E.
de Castro, Caio Cesar Silva
Marques, Silvio Alencar
Antonio, Joao Roberto
Fabricio, Lincoln
Soliman, Ahmed M.
Wu, Tianshuang
Sinvhal, Ranjeeta
Stakias, Vassilis
Song, Alexandra P.
Kalabic, Jasmina
Martin, Naomi
Oyafuso, Luiza Keiko Matsuka
ANAIS BRASILEIROS DE DERMATOLOGIA, 2025, 100 (02) : 260 - 271
[47] A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Yellin, Michael
Paliienko, Igor
Balanescu, Andra
Ter-Vartanian, Semen
Tseluyko, Vira
Xu, Li-An
Tao, Xiaolu
Cardarelli, Pina M.
LeBlanc, Heidi
Nichol, Geoff
Ancuta, Codrina
Chirieac, Rodica
Luo, Allison
ARTHRITIS AND RHEUMATISM, 2012, 64 (06): : 1730 - 1739
[48] The clinical efficacy and safety of subcutaneous (SC) versus oral application of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) - Results of a randomized, controlled, double-blind, multi-center study
Braun, J.
Kaestner, R.
Flaxenberg, P.
Waehrisch, J.
Henke, P.
Demary, W.
Von Hinueber, U.
Rockwitz, K.
Heitz, W.
Guimbal-Schmolck, C.
Pichlmeier, U.
Brandt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 87 - 87
[49] A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results
Choe, Jung-Yoon
Prodanovic, Nenad
Niebrzydowski, Jaroslaw
Staykov, Ivan
Dokoupilova, Eva
Baranauskaite, Asta
Yatsyshyn, Roman
Mekic, Mevludin
Porawska, Wieslawa
Ciferska, Hana
Jedrychowicz-Rosiak, Krystyna
Zielinska, Agnieszka
Choi, Jasmine
Rho, Young Hee
Smolen, Josef S.
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[50] Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Janusz Jaworski
Marco Matucci-Cerinic
Hendrik Schulze-Koops
Maya H. Buch
Eugeniusz J. Kucharz
Yannick Allanore
Arthur Kavanaugh
Philip Young
Goran Babic
Arthritis Research & Therapy, 21

← 1 2 3 4 5 →